Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Blood (2009) 114 (13): 2764–2773.

https://doi.org/10.1182/blood-2009-02-203547

Published: 2009

Includes: Supplemental data

Journal Articles

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Steven D. Gore, MD, Lawrence Morris, MD, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Mikkael A. Sekeres, MD, MS, Robert J. Arceci, MD, PhD, Robert L. Redner, MD, Tianna Dauses, BSN, Esther L Schachter-Tokarz, Ibitayo Owoeye, MD, Robert E. Gallagher, MD

Blood (2008) 112 (11): 1932.

https://doi.org/10.1182/blood.V112.11.1932.1932

Published: 2008

Journal Articles

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Robert E Gallagher, MD, Esther L Schachter- Tokarz, BA, Lawrence E. Morris, Tianna Dauses, BSN, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Robert L. Redner, MD, Mikkael A. Sekeres, MD, MS, Ibitayo Owoeye, MD, Steven D. Gore, MD

Blood (2008) 112 (11): 1502.

https://doi.org/10.1182/blood.V112.11.1502.1502

Published: 2008

Journal Articles

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

Steven D. Gore, MD, Anchalee Jiemjit, MS, Lewis B. Silverman, MD, Timothy Aucott, Stephen Baylin, MD, Hetty Carraway, MD, Tianna Dauses, BSN, Tamer Fandy, PhD, James Herman, MD, Judith E. Karp, MD, Jonathan D. Licht, MD, Anthony J. Murgo, MD, Rosalie Odchimar-Reissig, BSN, B. Douglas Smith, MD, James A. Zwiebel, MD, Elizabeth Sugar, PhD

Blood (2006) 108 (11): 517.

https://doi.org/10.1182/blood.V108.11.517.517

Published: 2006

Journal Articles

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Steven D. Gore, MD, Stephen B. Baylin, MD, Tianna Dauses, RN, Michael R. Grever, MD, Anchalee Jiemjit, MS, Jasper Manning, MS, Carole B. Miller, MD, Anthony J. Murgo, MD, James A. Zwiebel, MD, James G. Herman, MD

Blood (2004) 104 (11): 469.

https://doi.org/10.1182/blood.V104.11.469.469

Published: 2004

Journal Articles

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

B. Douglas Smith, Mark Levis, Miloslav Beran, Francis Giles, Hagop Kantarjian, Karin Berg, Kathleen M. Murphy, Tianna Dauses, Jeffrey Allebach, Donald Small

Blood (2004) 103 (10): 3669–3676.

https://doi.org/10.1182/blood-2003-11-3775

Published: 2004

NARROW

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only